Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen s Q4 Revenues Increase, Losses Widen

NEW YORK, Feb 15 - Buoyed by strong sales of its ProteinChip systems, Ciphergen reported $3 million in fourth quarter earnings, up from $2 million in 1999, while increased expenditures caused net losses to widen. 

Ciphergen's total revenues for 2000 increased 78 percent, to $8.9 million, from $5 million in 1999.

The company sold 19 ProteinChip systems in the fourth quarter of 2000, and 56 protein chip systems during the year. This brings the total number of protein chip systems Ciphergen has sold to 128.

"In 2000, Ciphergen completed a successful IPO and generated record growth, not just in revenue and system placements, but also in laying the foundation for the future," William Rich, Ciphergen CEO, said in a statement. "We invested aggressively in our sales and R&D organizations, and expect that this investment will start to have a major impact during 2001 and beyond."

Ciphergen's expenses increased for the fourth quarter to $8.7 million from $3.2 million from the year ago period. Research and development increased to $2.6 million from $901,000, and sales and marketing expenses rose to $2.8 million from $1.3 million. General and administrative expenses also increased, to $3.2 million from $996,000.

Total expenses for the year more than doubled to $28.1 million up from $11.3 million for 1999.

Ciphergen's net losses also rose significantly, from to $4.9 million, or 19 cents a share million, from $1.9 million, or 29 cents a share, in the year-ago quarter. The company had fewer shares outstanding in 1999 as compared with 2000.

The company missed Wall Street forecast for net loses of 17 cents a share for fourth-quarter 2000, according to a survey of brokers conducted by FirstCall/Thomson Financial.  
The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.